×

Watch Video

First Name
Last Name
Phone Number
Thank you!
Error - something went wrong!

Operationalizing the NIH Single IRB Mandate

The National Institutes of Health’s (NIH) new policy mandating the use of a single Institutional Review Board (sIRB) for all multi-site studies goes into effect in September 2017. Are you ready?
 
Many hospitals and academic medical centers (AMCs) are scrambling to plan for the complex and burdensome process surrounding multi-site, single IRB review. In particular, the coordination of site submissions and vital communications, and reliable budgeting for IRB review of multi-year, investigator-initiated research projects are challenges that these institutions will be facing – many for the first time. How then, can institutions prepare for this new mandate, all while allowing their research teams to focus on doing their research?
 
With a newly formed partnership designed to help institutions improve the effectiveness of their clinical research programs, WIRB and Huron have compiled a list of five important milestones that institutions will need to address when planning to comply with this new policy. 
 
Access this webinar to learn what best-practices institutions can adopt to make it easy to plan, submit, and conduct their NIH-funded studies as efficiently, compliantly, and safely as possible.

About the Author

David Forster, JD, MA, CIP | Chief Compliance Officer

Mr. Forster has a J.D. and a Masters in Medical Ethics from the University of Washington. He joined Western IRB (WIRB) in 1996 and is currently the Chief Compliance Officer for the WIRB-Copernicus Group (WCG). Mr. Forster co-chairs the Secretary’s Advisory Committee on Human Research Protections (SACHRP) Sub-Committee on Harmonization (SOH). He previously served a four-year term as a member of SACHRP, and was a member of the SACHRP Sub-Committee on Inclusion of Individuals with Impaired Decision-Making in Research (SIIIDR). Mr. Forster also serves on the Certified IRB Professional (CIP) Council.

Follow on Linkedin More Content by David Forster, JD, MA, CIP | Chief Compliance Officer
Previous Flipbook
Institutional IRB Performance: Optimizing and Benchmarking Report, 2015
Institutional IRB Performance: Optimizing and Benchmarking Report, 2015

Next Video
Early Access to Investigational Drugs: Lessons Learned from Ebola
Early Access to Investigational Drugs: Lessons Learned from Ebola

Learn about the regulatory framework that governs the use of investigational drugs outside clinical trials ...